在冠状动脉疾病中重新考虑静止剂剂量
Simon B Dimmitt1,2, Hans G Stampfer3, Michael C Kennedy4
1Division of Internal Medicine, Medical School, University of Western Australia, Crawley, Australia.
Pharmacology research & perspectives
|December 16, 2025
概括
类药物是唯一被证明可以提高存活率的胆固醇药物,但中等剂量为心血管疾病患者提供最大的益处,风险较小. 高剂量显示死亡率降低最小.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 心血管疾病的管理依赖于风险因素控制和再血管化.
- 尽管有证据,但在全球 (<3%) 和发达国家 (~10%),他类药物的吸收仍然很低.
- 类他类药物是唯一被证明可以降低死亡率的降低胆固醇的药物,主要是在症状冠心病患者中,在中等剂量范围内.
研究的目的:
- 评估不同剂量他类药物对心血管疾病的疗效和安全性.
- 为了确定最佳的胆固醇目标,以最大限度地提高生存率.
- 为了比较他类药物的疗效与较新的降脂剂.
主要方法:
- 对有关胆固醇水平和死亡率的人口研究的综述.
- 对六项大型随机对照试验 (RCT) 的分析,比较高剂量与中等剂量的他类药物.
- 对PCSK9抑制剂和ezetimibe等新药的数据的检查.
主要成果:
- 人口研究表明,随着胆固醇的降低,冠状动脉事件和死亡率较低,但总死亡率低于5mmol/L.
- 风险试验表明,在使用较高剂量的他类药物时,冠状动脉事件的边际减少,但死亡率没有显著下降.
- 较新的降脂药物没有证明改善死亡率的好处.
结论:
- 中等范围的他类药物剂量在心血管疾病患者的总死亡率上取得了最大的改善.
- 较高的他类药物剂量增加了毒性,但没有显著的死亡率益处.
- 最佳管理包括足够的他类药物剂量,减肥和其他药物治疗.
关键词:
不良事件不良事件不良事件在此之前,Atheroma 已经出现了.胆固醇 胆固醇 胆固醇 是一种冠状动脉疾病是一种冠状动脉疾病.有效剂量50 (ED50)斯塔丁 (Statin) 是一种类型的药物.更多相关视频
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
14.0K
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
9.7K
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:26Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
01:26Coronary Artery Disease IV: Preventive Measures
572
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
572
01:27Coronary Artery Disease V: Interprofessional Care
203
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
203
01:26Angina IV: Management
215
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
215
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
236
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
236